ABSTRACT
INTRODUCTION
Hepatitis C virus (HCV) infection is a major health problem worldwide, affecting more than 170 million people [1] . HCV infection is a common cause of chronic liver disease, which may progress to hepatocellular carcinoma, and it is the most common indication of liver transplantation [2] . Current treatment is based on the association between pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV). This treatment is effective in about 55% of patients [3, 4] . Treatment outcome has been shown to be influenced by viral factors such as the HCV RNA baseline or HCV genotype [5] , as well as by host factors such as obesity, cirrhosis, ethnic background, or fibrosis [6] .
The World Health Organization defines obesity as an abnormal or excessive fat accumulation in adipose tissue, to the extent that health is impaired [7] . Obesity is major public health issue with a rapidly increasing prevalence [8] . Obesity, genetic susceptibility, aging, and male sex were found to be associated with increased visceral fat accumulation [9] . Despite having lower average body mass index (BMI) than whites, Asian women have a higher degree of central adiposity for a given BMI [10] , which confers an increased risk for metabolic syndrome, type 2 diabetes, and cardiovascular diseases [11] , [12] . In particular, visceral adiposity has been reported to play a key role in these diseases compared with other measurements of regional or generalized obesity [13] .
Visceral adipose tissue is believed to secrete a variety of substances that regulate the metabolism and participating in the pathogenesis of liver damage. Metabolic factors have been associated with liver damage in patients with HCV especially genotype 1. Amato, et al. [14] demonstrated that in genotype 1 HCV patients, higher visceral adiposity index (VAI) score is independently associated with both steatosis and necroinflammatory activity and has a direct correlation with viral load. The whole body magnetic resonance imaging (MRI) is the gold standard technique to accurately measure visceral adiposity [15] . Waist circumference (WC) as a measure of visceral adiposity may be less reliable in older persons [16] . BMI is considered a poor indicator of cardiovascular risk than WC across ethnicities, suggesting that BMI may not be a very good measure of visceral adiposity [17] . In the light of limitations and lack of exciting methods and the recognition that more reliable measure of visceral adiposity are needed. Amato, et al. [14] proposed the modification of Model Of Adipose Distribution (MOAD). To correct MOAD for fat function, triglyceride and High density lipoprotein (HDL) levels were introduced in the formula.
This was defined as VAI:
MATERIALS AND METHODS
This observational prospective study was carried out at the internal medicine, faculty of All the patients fulfilling the inclusion criteria were treated according to the treatment protocol based on response-guided therapy [18] . Patients were treated with standard PEG-IFN-α and RBV therapy according to the American Association for the Study of the Liver Diseases (AASLD)
guidelines [6] . Briefly, patients with chronic HCV infection received subcutaneous peg-IFNα-2b at a dose of 1.5 μg/kg once weekly, and oral RBV at a dose of 600-1000 mg twice daily, adjusted according to body weight (600 mg for weight of 60 kg or less, 800 mg for weight of 60-80 kg or less, and 1000 mg for weight above 80 kg) or peg-IFNα-2a at a dose of 180 μg/kg once weekly, and oral RBV at a dose of 1000-1200 mg twice daily, adjusted according to body weight (1000 mg for weight of 70 kg or less, 1200 mg for weight above 70 kg). The standard treatment duration lasted 48 weeks. Patients who discontinued treatment within 24 weeks of treatment for reasons other than virological failure were excluded. During treatment, patients were assessed as outpatients at weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 , and at 48, and then at 24 weeks after the end of the therapy. Liver biopsy specimens were reviewed using the METAVIR scoring system for staging of fibrosis and grading of necroinflammation activity [19] . The serum HCV RNA was assessed using a quantitative PCR assay (COBAS TaqMan HCV test, Roche Diagnostics). PCR was done at weeks 0, 12, 24 and 48. At each visit, blood cell counts and ALT were measured and recorded. VAI was assessed at basal time (before beginning of treatment), at weeks 24 and 48. Side effects were also recorded at each visit. 
Classification of Response

Anthropometric and Body Fat Assessment
The following anthropometric measurements were obtained: Weight was assessed by a balance-beam scale while the participant was wearing lightweight clothing. Standing height was assessed by a stadiometer. BMI was calculated by the Quetelet index: weight in kilograms/height in meters squared (kg/m 2 ) [20] . WC was measured by use of a metal tape measure at the maximum WC between the lower rib and the iliac crest. Participants were asked to stand with their weight equally distributed on both feet, with arms hanging at their sides and head facing straight ahead, relaxing their abdomen and breathing normally. The measurement was made at the end of a normal expiration to the nearest 0.1 cm. The measurement was taken twice and the final WC value used was the mean of the 2 or 4 recorded values.
Biochemical Tests
Blood chemistry analyses were performed in Alahrar laboratories of the National Health Service in Zagazig. After fasting for 12 h, venous blood was taken for estimation of blood sugars, complete liver function, and complete blood picture. Tests for triglyceride were performed on Hitachi Chemistry analyzers with Roche chemistry reagents; settings were as specified by the manufacturer. HDL cholesterol was determined by precipitation with phosphotungstic acid, Sigma
Chemical Reagent for in vitro diagnosis. Glomerular Filtration Rate (GFR) was estimated from serum creatinine using the MDRD formula and was expressed as ml/min/1.73 m 2 [21] . VAI score was calculated as described [14, 22] using the following sex-specific equations, where TG is Triglycerides levels expressed in mmol/l and HDL is HDL-Cholesterol levels expressed in mmol/l:
Statistical Analysis
Statistical analysis was performed using SPSS version 15.0 (SPSS Inc, Chicago, IL). Data are expressed as mean SD, or geometric mean and 95% confidence interval (CI) for variables requiring logarithmic transformation. Statistical significance was defined as P 0.05.
RESULTS
Response rates to standard PEG-IFN-α plus RBV therapy was studied over a 2 years period. A total of 50 patients were evaluated for the influence of potentially important factors on SVR. patients. In the total of 50 patients, EOTCR was seen in 56% (n=28 patients (m/f=24/4)), whereas 18% (n=9 patients (m/f=6/3)) were NR, and whereas 26% (n=13 patients (m/f=11/2)) were breakthroughers (BT). SVR was seen in 40% (n=20 (m/f=16/4)) patients, 16% (n=8 male patients)
were relapsers giving a relapse/non-response/break-through rate of 60%. The Baseline demographic and clinical characteristics of our studied patients are present in table 1. The effect of demographic and clinical characteristics on achieving EVR is given in Table 2 . During the course of treatment and follow up of our patients, we found that there were high significant differences in the EVR group between the basal reading and 24 week reading for weight, BMI, WC, triglyceride, and VAI (P < 0.05); but no significant difference for HDL (P > 0.05). About the EOTCR, there were also high significant differences between the basal reading and 24 week reading for weight, BMI, WC, and triglyceride (P <0.001, for all) and significant difference for VAI (P < 0.05), but no significant difference for HDL (P > 0.05). Also, About the SVR, there were also high significant differences between the basal reading and 24 week reading for weight, BMI, WC, and triglyceride (P <0.001, for all) and significant difference for VAI (P < 0.05), but no significant difference for HDL (P > 0.05). By comparing the results between the three groups (EVR, EOTCR, and SVR), we found that there were no significant differences for all variables except there was significant difference between the EOTCR and SVR groups for VAI at 48 week (P = 0.016). The VAI was less in the SVR group in comparison to the EOTCR at 48 week (mean + SD = 1.77 + 0.7 and 1.6 + 0.56, respectively). Also, we found that there were significant differences in the Breakthrough group between the basal reading and 24 week reading for weight, BMI, WC, and triglyceride (P < 0.05); but no significant difference for HDL and VAI (P > 0.05). By comparing the results of basal reading and 48 week for weight, BMI, triglyceride, and VAI; we found that there were significant differences between these variables (P < 0.05); but no significant difference for WC and HDL (P > 0.05). By comparing the results of 24 week reading and 48 week for weight, BMI, WC, HDL, and VAI; we found that there were no significant differences between these variables (P > 0.05); but there was significant difference for triglyceride (P < 0.05). About the Relapse group, there were also significant differences between the basal reading and 24 week reading for weight, BMI, WC, and triglyceride (P < 0.05) and no significant difference for HDL and VAI (P > 0.05). By comparing the results of basal reading and 48 week for weight, BMI, HDL, and VAI; we found that there were no significant differences between these variables (P > 0.05); but there were significant difference for WC and triglyceride (P < 0.05). By comparing the results of 24 week reading and 48 week for weight, BMI, WC, HDL, and VAI; we found that there were no significant differences between these variables (P > 0.05); but there was significant difference for triglyceride (P < 0.05). By comparing the results between the three groups (NR, Breakthrough, and Relapse), we found that there were no significant differences. We gathered the whole patients who did not achieve the target response of treatment (NR, Breakthrough, and relapsers) in a one group called failure group. By comparing the result of this group with SVR group, we found that there were no significant differences between the basal reading of the two groups for age, height, weight, BMI, WC, HDL, fibrosis stage, and viral load (P > 0.05); but there were significant difference for triglyceride and VAI (P < 0.05). By comparing the results of 24 week reading of the two groups for weight, BMI, WC, triglyceride, HDL, and VAI;
we found that there were no significant differences between these variables (P > 0.05). By comparing the results of 48 week reading of the two groups for weight, BMI, WC, and HDL; we found that there were no significant differences between these variables (P > 0.05); but there was significant difference for triglyceride and VAI (P < 0.05). About the failure group, there were high significant differences between the basal reading and 24 week reading for weight, BMI, WC, and triglyceride (P < 0.05) and no significant difference for HDL and VAI (P > 0.05). By comparing the results of basal reading and 48 week for weight, BMI, WC, triglyceride, HDL, and VAI; we found that there were significant differences between these variables (P < 0.05). By comparing the results of 24 week reading and 48 week for weight, BMI, WC, and HDL; we found that there were no significant differences between these variables (P > 0.05); but there was significant difference for triglyceride and VAI (P < 0.05). About the SVR group, there were high significant differences between the basal reading and 24 week reading for weight, BMI, WC, triglyceride, and VAI (P < 0.05) and no significant difference for HDL (P > 0.05). By comparing the results of basal reading and 48 week for weight, BMI, WC, triglyceride, HDL, and VAI; we found that there were high significant differences between these variables (P < 0.05). By comparing the results of 24 week reading and 48 week for weight, BMI, WC, and VAI; we found that there were no significant differences between these variables (P > 0.05); but there was high significant difference for triglyceride and HDL (P < 0.05).
DISCUSSION
Currently, the combination of PEG-IFN-α and RBV is the treatment of choice for patients with chronic hepatitis C. Unfortunately this treatment is very challenging. Antiviral treatment is very expensive, often has many side effects, and lasts too long up to 48 weeks for genotype 1 and 4 with a limited SVR rate (50-60%). Moreover, there is a group of HCV infected patients that are not good candidates for PEG-IFN-α and RBV due to systemic diseases. Although there are new therapies in development, it's likely that PEG-IFN-α/RBV will remain the mainstay of HCV treatment for the near future. Probably PEG-IFN-α and RBV will continue to be administered together with protease or polymerase inhibitors of HCV replication. Thus, due to an overall low response to standard HCV therapy, it would be important to predict during the pre-treatment evaluation period those patients who will respond treatment as well as those who will not. In addition, it would also be important to help decide for whom to start treatment and when to stop the therapy. Predicting SVR to HCV treatment before the beginning of therapy is possible by different well known host and virus related factors as BMI, pre-treatment HCV RNA level, and doses of
interferon. Yet none of these have been able to accurately and consistently predict the patients who will respond to interferon [23] . So we studied the predictability of visceral adiposity as a pretreatment and during treatment predictor for SVR in HCV.A low response to treatment is generally associated with male gender; females are considered to be better responders to interferon based treatments [24] . It was not observed in this study. The difference was not statistically significant between the failure group and the SVR group (P>0.05). Age is also considered to be a weak predictor of response [25] . Age below 40 years is associated with better response, again not seen in this study. SVR were between 22-45 years of age and the differences between them and the failure patients were not statistically significant (P>0.05). A low baseline body weight is predictor of a SVR and increased body weight has been shown to be associated with low SVR in genotypes 1, 2 and 3 [25] . This was found to be statistically not significant in this cohort of patients as SVR group when compared to failure group had nearby weights (P > 0.05) and also EVR group when compared to NR group had nearby weights (P > 0.05). The effect of weight is limited as a predictor of response because both responder and non-responder had a significant change of weight during treatment. There were weight reductions in both. Hany, et al. [26] found that spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with improved EVR and weight loss at 4
weeks was an independent predictor of EVR. However, weight loss at 4 and 12 weeks of therapy was not a predictor of SVR. SVR is constantly higher in patients with low HCV RNA levels regardless of genotype. Manns [4] in an original study that compared peg INF/RBV with INF/RBV
showed that those with a viral load lower than 2 10 6 copies/ml had a SVR of 78% compared with a SVR of 42 in those with a viral load higher than 2 10 6 copies/ml. Nowadays there is a debate about the real definition of a low viral load and who will be candidates for a reduced duration of treatment based on the fourth week response. In our study, there was no significant difference in the viral load of SVR and the failure group as a whole (P>0.05). But early at 12 week response, there was significant difference between the EVR and NR (P < 0.05). Iacobellis, et al. [27] found that SVR in patients with advanced fibrosis (Metavir F3/F4) was achieved in 8% -44%, depending on the treatment adopted and the intensity of liver dysfunction. The same study has shown that in patients with mild disease (Metavir F0/F1) the SVR could reach 74% even in genotype 1 patients.
In our study, we did not studied patients with F0/F4. According to our patients there was no significant difference between the EVR and NR at 12 week (P= 0.594) (In EVR group, F1 / F2 / F3 comprise 20% / 44% / 18% and NR group, F1 / F2 / F3 comprise 0% / 14% / 4%; respectively). At 48 week, also there was no significant difference between the SVR and the failure group (P=0.163) (In SVR group, F1 / F2 / F3 comprise 4% / 38% / 18% and NR group, F1 / F2 / F3 comprise 16% / 20% / 4%; respectively). Numerous techniques have been developed to assess visceral fat. The most clinically expedient are those that can be performed quickly and bedside without extensive technical training. However, visceral adipose tissue (VAT) is only an indirect measure when using these approaches. Only CT and MRI can provide direct measures of cross-sectional areas or volumetric measures of VAT [28] . In our study we depend on these simple, quick, and bedside indirect methods of VAT measurement. Although the VAI was modelled on a Caucasian population, several studies confirm the validity of its use with other races. For example, in a large case-control study, a high VAI is associated with elevated risk of CHD in Chinese men and women [29] . Moreover, in a large cross-sectional study on 1,764 primary care patients, appropriate stratified-for-age cut-offs were identified that were able to identify a supposed adipose tissue dysfunction (ATD) [30] (Table 6 ). These cut-offs have been more or less confirmed in a recent study [31] in which ATD was directly investigated through a large panel of proinflammatory adipokines. In the field of hepatology, the VAI has been investigated in several studies in patients with NAFLD, with the main objective of identifying a clinical marker predictive of evolution towards necroinflammatory injury and fibrosis [32] [33] [34] [35] [36] [37] . In this respect, there are contrasting results between the various studies, since according to some authors the VAI accurately predicted progressive liver histology more accurately than other validated noninvasive scores and identified patients with NAFLD at increased CVD risk [32, 34, 37] , while according to other authors [32, 33, 35, 36 ] the VAI is not more powerful than other anthropometric indices in discriminating steatosis from steatohepatitis. Another opinion, these discrepancies are attributable to differences between the patients enrolled, especially concerning the variables included in the VAI. This especially applies to the mean of triglyceride levels in the various populations [22] . Moreover, an interesting result was obtained from a study [38] on patients with chronic HCV due to genotype 1. In these patients only older age, high VAI, and fibrosis were independently associated with moderate-severe necroinflammatory activity by a logistic regression analysis; a higher VAI also has a direct correlation with viral load. Probably, ATD (indirectly expressed by the VAI) by way of free fatty acid and proinflammatory cytokine secretion could directly participate in both liver steatosis and induction of inflammation. In this complex interplay between the liver and adipose tissue, HCV could have an important role. It is possible not only that adipose tissue could provide fatty substrates and a proinflammatory status, favouring HCV replication, but also that HCV could interfere with adipocyte function indirectly by increasing the inflammatory status and directly by colonizing adipocytes or immune cells infiltrating adipose tissue [39, 40] .
In our study, there was no significant difference in VAI between the EVR group and the NR group at the basal reading before the start of treatment (P= 0.102). By comparison of the result of VAI of the failure group and the SVR at various times of the study, we found that there was significant difference between the two groups at basal reading (P= 0.043) and at the end of the study (48 week) (P= 0.045). But there was no significant difference between the two groups at 24 weeks (P= 0.191). By comparison of the VAI of the failure group at various times of the study, we found that there was no significant difference between the basal reading and the 24 week reading (P= 0.239), but there was significant difference between the basal reading and the 48 week reading (P= 0.024) and the 24 week reading and the 48 week reading (P= 0.042). By comparison of the VAI of the SVR group at various times of the study, we found that there was significant difference between the basal reading and the 24 week reading (P= 0.014) and between the basal reading and the 48 week reading (P= 0.022), but there was no significant difference between the 24 week reading and the 48 week reading (P= 0.628).
By comparison of VAI of subjects with virologic response to HCV therapy during various stages of the study, we will notice that there was no significant difference between the three groups (EVR, EOTCR, SVR) by comparing the basal readings (P= 0.212) and also by comparing the 24 week readings (P= 0.147) but there was significant difference by comparing the 48 week between the EOTCR and SVR (P = 0.016). Inside each group, there was high significant difference between the basal reading and 24 week reading in EVR (P = 0.008), the basal reading and 24 week in EOTCR (P = 0.046), the basal reading and 48 week reading in EOTCR (P = 0.035), the basal reading and 24 week reading in SVR (P = 0.014), and basal reading and 48 week reading in SVR (P = 0.022). There were no significant difference between the 24 week and 48 week readings in EOTCR (P = 0.757) and the 24 week and 48 week readings in SVR (P = 0.628). From the previous results, we will note that there were significant changes in VAI from the start of therapy to the 24 week in the responder patients which may result in continuation of response to the end of therapy.
By comparison of VAI of subjects with virologic without response to HCV therapy during various stages of the study, we will notice that there was no significant difference between the three groups (NR, breakthrough, Relapse) by comparing the basal readings (P= 0.434) and also by comparing the 24 week readings (P= 0.649) between the breakthrough and relapse groups and also by comparing the 48 week readings (P= 0.644) between the breakthrough and relapse groups.
Inside each group, there was significant difference between the basal reading and 24 week reading in breakthrough (P = 0.079), the basal reading and 48 week reading in breakthrough (P = 0.021).
There were no significant difference between the 24 week and 48 week readings in breakthrough (P = 0.137) and the basal reading and 24 week readings in relapse group (P = 0.725), the basal reading and 48 week readings in relapse group (P = 0.520), and the 24 week and 48 week readings in relapse group (P = 0.181). From the previous results, we will note that there were significant changes in VAI from the start of therapy to the 24 week in the breakthrough group but no in the relapse and the VAI reading in both breakthrough and relapse groups tend to be high at 48 week which may result in loss of response to the end of therapy. By analyzing the previous results, we will note that the VAI in SVR group has mild elevation during the first 24 weeks of the study course staring from low normal values and then nearly no change during the following weeks (1.27 + 0.7; 1.67 + 0.6; 1.6 + 0.56). The same changes occur in the EVR and EOTCR. In the NR group the starting (basal) VAI was high in comparison to that of SVR (1.9 + 0.9 and 1.27 + 0.7, respectively). The same was noticed in the breakthrough and relapse group. Also in contrast to the SVR, there were marked and continued elevations of the VAI during the study course in the two groups (1.58 + 0.9; 1.88 + 0.9; 2.25 + 0.6 and 1.94 + 0.5; 1.86 + 0.6; 2.19 + 0.9, respectively). By doing ROC curve analysis, we can obtain the following table (Table 7) for various cutoff values of VAI during the different stages of treatment course which can predict the response to treatment and predict the SVR patients. 
CONCLUSION
In conclusion, this work presents a simple and reliable pre-therapy tool to identify unlikely and anticipated responders to treatment with Peg-IFN plus RBV in HCV-infected patients, including clinical and laboratory parameters. Three of these parameters were routinely used many years ago (weight, BMI, WC) and the other has been recently incorporated into clinical practice (triglyceride, HDL, VAI). This tool may be used to select HCV-infected candidates for immediate and, more importantly, deferred therapy against HCV and it is able to identify as anticipated or unlikely responders in respectable ratio of patients.
